D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment
Case report
Background:
Severe allergic asthma patients often require subcutaneous immunotherapy (SCIT) to manage symptoms, especially those with high sensitivity to environmental allergens like Birch (PR10). Despite adherence to established protocols, some patients experience persistent reactions. This case report highlights a 53-year-old male with severe asthma, allergic to Birch, who underwent SCIT for Birch desensitization. Despite premedication and strict protocol adherence, the patient developed recurrent reactions after each injection. Elevated tryptase levels were observed during these reactions, suggesting mast cell activation. This case prompts a reevaluation of the role of tryptase in monitoring high-risk patients undergoing immunotherapy.
Case Presentation:
A 53-year-old male with severe asthma, sensitized to Birch, began SCIT for Birch desensitization. Although he received premedication and followed standard protocols, recurrent reactions occurred after each injection. Symptoms included mild bronchoconstriction, wheezing, and skin reactions, managed with antihistamines and corticosteroids. However, his reactions persisted, prompting further investigation into his immunological response. Blood tests revealed significantly elevated tryptase levels 22 ng/mL following these reactions, indicating mast cell degranulation.
Discussion:
The elevated tryptase levels suggest mast cell activation during SCIT, a potential contributor to recurrent reactions. Tryptase is released during allergic reactions, particularly in cases of anaphylaxis, and is a marker of mast cell degranulation. Despite premedication and protocol adherence, the elevated tryptase indicates this patient may be at higher risk for severe allergic responses. This case underscores the importance of monitoring tryptase levels in high-risk patients, particularly those with severe asthma and complex allergic profiles. Elevated tryptase could act as an early indicator of mast cell activation, potentially guiding decisions about dose adjustments or alternative therapies.
Conclusion:
This case highlights the potential utility of elevated tryptase as a biomarker for monitoring patients undergoing SCIT, particularly those with severe asthma. Regular testing for tryptase levels could provide valuable insights into the severity of allergic reactions, allowing for more personalized treatment strategies and timely interventions. Incorporating tryptase measurements into clinical practice could enhance patient safety and improve the overall effectiveness of immunotherapy in complex allergic conditions.
